Loading…
Immutep Limited is projected to rise to $0.6084 by 2027, a +40% move from its current price of $0.4346. IMMP is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $0.4138 | $0.4353 | $0.4579 | +0.15% |
| May 30 | $0.4058 | $0.4359 | $0.4683 | +0.31% |
| May 31 | $0.3999 | $0.4366 | $0.4767 | +0.46% |
| Jun 1 | $0.3952 | $0.4373 | $0.4839 | +0.62% |
| Jun 2 | $0.3911 | $0.438 | $0.4905 | +0.77% |
| Jun 3 | $0.3874 | $0.4386 | $0.4966 | +0.93% |
| Jun 4 | $0.3842 | $0.4393 | $0.5023 | +1.09% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $0.3842 | $0.4393 | $0.5023 | +1.09% |
| Week 2 | $0.3674 | $0.4441 | $0.5368 | +2.18% |
| Week 3 | $0.3559 | $0.4489 | $0.5662 | +3.29% |
| Week 4 | $0.3471 | $0.4538 | $0.5933 | +4.41% |
| Week 5 | $0.3399 | $0.4587 | $0.619 | +5.54% |
| Week 6 | $0.3339 | $0.4637 | $0.6439 | +6.69% |
| Week 7 | $0.3288 | $0.4687 | $0.6682 | +7.85% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Immutep Limited is a biotechnology company that develops novel LAG-3 related immunotherapies for cancer and autoimmune diseases in Australia.
Its lead product candidate is eftilagimod alfa (efti or IMP321), a soluble LAG-3lg fusion based on the LAG-3 immune control mechanism for treating different types of cancers. The product pipeline also includes TACTI-004 (phase III for first-line NSCLC); TACTI-003 (phase IIb for first-line HNSCC); INSIGHT-005 (phase I for metastatic urothelial carcinoma); TACTI-002 (phase II for NSCLC and HNSCC); AIPAC-003 (phase II/III for metastatic breast cancer); EFTISARC-NEO (phase II for soft tissue sarcoma). It also develops INSIGHT-003 (phase I for 1L non-squamous NSCLC); INSIGHT-005 (phase I for metastatic urothelial cancer); IMP761 (phase I for autoimmune disease); IMP731 (for oncology and autoimmune diseases); and LAG525.
Immutep has collaborations with Merck & Co., EOC Pharma, Novartis, and Laboratory Corporation of America Holdings. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. The company was incorporated in 1987 and is based in Sydney, Australia.
Immutep Limited (IMMP) currently trades at $0.4346, with a market cap of $64.05M and a rank of 4433. The stock’s price outlook is defined by a year-by-year forecast that shows modest upside from 2027 onward, with the 2026 average price listed as $0.4346 and higher averages emerging through 2050 (e.g., 2027 $0.6084, 2028 $0.7108, 2040 $1.19, 2050 $1.49). The forecast also indicates higher potential in later years, with a max price forecast reaching $3.42 by 2050 and a sustained bullish sentiment from 2027 onward.
A major floor 30.2% below — a decisive break under it would weaken the trend.
Price is testing support right now (1.1% away) — a key level to hold.
The nearest ceiling, 42.7% above — a clean break opens room to run.
A major ceiling 631.7% above — clearing it would confirm fresh momentum.
Key IMMP support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of IMMP market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $0.464 | Sell | $0.4584 | Sell |
| MA 10 | $0.474 | Sell | $0.4663 | Sell |
| MA 20 | $0.4635 | Sell | $0.4812 | Sell |
| MA 50 | $0.4426 | Sell | $0.7435 | Sell |
| MA 100 | $1.60 | Sell | $1.19 | Sell |
| MA 200 | $1.78 | Sell | $1.55 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 37.61 | Neutral |
| Stoch RSI (14) | 43.75 | Neutral |
| CCI (20) | -116.32 | Sell |
| Williams %R (14) | -100.00 | Info |
| MACD (12,26,9) | 0.01 | Buy |
| ROC (12) | -4.44 | Sell |
| Bollinger %B (20,2) | 0.14 | Neutral |
| Stochastic %K (14) | 0.00 | Buy |
| TRIX (15) | -1.13 | Sell |
| Awesome (5,34) | -0.01 | Sell |
| Ultimate (7,14,28) | 30.52 | Neutral |
| Momentum (10) | -0.04 | Sell |
| Aroon Osc (25) | -96.00 | Sell |
| Hull MA (9) | 0.45 | Sell |
| ADX (14) | 27.66 | Sell |
| ATR (14) | 0.03 | Info |
The 30-day technical picture is NEUTRAL. RSI14 is 40. The 50-day simple moving average sits at $0.4426, while the 200-day simple moving average sits at $1.78. Support is at $0.43 and resistance at $0.62.
The 30-day trading range runs from $0.3112 to $0.6069, signaling limited near-term upside from the current level. The asset shows an annualized volatility of 100%, underscoring the notable price swings typical of this stock.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $0.31 | $0.4346 | $0.7324 | 0% | Neutral | |
| $0.4425 | $0.6084 | $0.9041 | +40% | Bullish | |
| $0.489 | $0.7108 | $1.12 | +64% | Bullish | |
| $0.3917 | $0.5973 | $0.9853 | +37% | Bullish | |
| $0.3362 | $0.5356 | $0.9177 | +23% | Bullish | |
| $0.3583 | $0.5945 | $1.05 | +37% | Bullish | |
| $0.3741 | $0.6451 | $1.18 | +48% | Bullish | |
| $0.4768 | $0.8535 | $1.60 | +96% | Bullish | |
| $0.4699 | $0.872 | $1.67 | +101% | Bullish | |
| $0.3906 | $0.7511 | $1.47 | +73% | Bullish | |
| $0.534 | $1.19 | $2.55 | +173% | Bullish | |
| $0.6692 | $1.49 | $3.42 | +242% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $0.31 | $0.4346 | $0.5137 | +0.00% |
| June 2026 | $0.3776 | $0.4519 | $0.5596 | +3.98% |
| July 2026 | $0.4114 | $0.5002 | $0.6346 | +10.69% |
| August 2026 | $0.4111 | $0.5061 | $0.654 | +1.18% |
| September 2026 | $0.4005 | $0.4983 | $0.6535 | -1.54% |
| October 2026 | $0.4228 | $0.5312 | $0.706 | +6.59% |
| November 2026 | $0.4383 | $0.5553 | $0.7467 | +4.54% |
| December 2026 | $0.4218 | $0.5388 | $0.7324 | -2.97% |
Click any year to see its month-by-month IMMP forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
By 2026, IMMP could reach as high as $0.7324, with a base case around $0.4346 and support toward $0.31 — roughly 0% from $0.4346. Price action looks broadly range-bound.
Expect IMMP to range from $0.4425 to $0.9041 through 2027. The $0.6084 average target implies a +40% move from current prices. That is up +40% on the projected 2026 average. Buyers look set to stay in control over this stretch.
The IMMP price prediction for 2028 points to an average of $0.7108 (low $0.489, high $1.12) — a potential gain of +64% on today's $0.4346. Momentum favours further upside here.
In 2029, IMMP is projected to trade between $0.3917 and $0.9853, averaging $0.5973 — a potential gain of +37% from today's $0.4346. That is -16% versus the projected 2028 average. Buyers look set to stay in control over this stretch.
Immutep Limited's 2030 outlook centres on $0.5356, within a $0.3362 to $0.9177 range. That is -10% versus the projected 2029 average. That marks a +23% change versus current levels. Momentum favours further upside here.
By 2031, IMMP could reach as high as $1.05, with a base case around $0.5945 and support toward $0.3583 — roughly +37% from $0.4346. Buyers look set to stay in control over this stretch.
Expect IMMP to range from $0.3741 to $1.18 through 2032. The $0.6451 average target implies a +48% move from current prices. That is up +9% on the projected 2031 average. Momentum favours further upside here.
The IMMP price prediction for 2033 points to an average of $0.8535 (low $0.4768, high $1.60) — a potential gain of +96% on today's $0.4346. Buyers look set to stay in control over this stretch.
In 2034, IMMP is projected to trade between $0.4699 and $1.67, averaging $0.872 — a potential gain of +101% from today's $0.4346. That is up +2% on the projected 2033 average. Momentum favours further upside here.
Immutep Limited's 2035 outlook centres on $0.7511, within a $0.3906 to $1.47 range. That is -14% versus the projected 2034 average. That marks a +73% change versus current levels. Buyers look set to stay in control over this stretch.
By 2040, IMMP could reach as high as $2.55, with a base case around $1.19 and support toward $0.534 — roughly +173% from $0.4346. Momentum favours further upside here.
Expect IMMP to range from $0.6692 to $3.42 through 2050. The $1.49 average target implies a +242% move from current prices. That is up +25% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in IMMP today (≈ 2,300.966406 IMMP) could be worth
$3,421.61
+$2,421.61 (+242%) by 2050 · US Dollar
Based on the average projected IMMP price of $1.49 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in IMMPwould be worth at today's price.
$1,000 invested in IMMP on May 27, 2025 (≈ 502.51256 IMMP) would be worth
$218.39
-$781.61 (-78.2%) today · 0.22× · US Dollar
Based on a IMMP entry price of $1.99 vs. today's $0.4346.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $0.47 | $924.68 | -7.5% |
| 1 month ago | $0.52 | $835.77 | -16.4% |
| 3 months ago | $2.74 | $158.61 | -84.1% |
| 6 months ago | $2.03 | $214.09 | -78.6% |
| 1 year ago | $1.99 | $218.39 | -78.2% |
| All time (5.0y) ago | $5.21 | $83.42 | -91.7% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our IMMP forecast.
Our base-case forecast reaches $0.87 around 2034.
Implied market cap at $0.87: $128.21M
The multi-year forecast presents a bullish trajectory from 2027 onward, with 2026 showing a neutral stance before sentiment turns positive. The projected averages rise over time, with 2027 at $0.6084 and 2028 at $0.7108, progressing toward higher levels by 2040 ($1.19) and 2050 ($1.49).
Key ROI milestones include 2027 at 40%, 2028 at 63.5%, 2029 at 37.4%, 2030 at 23.2%, 2031 at 36.8%, 2032 at 48.4%, 2033 at 96.4%, 2034 at 100.7%, 2035 at 72.8%, 2040 at 173.1%, and 2050 at 242.2%. The forecast carries bullish sentiment across most of the horizon, with optimism that prices could rise meaningfully relative to today, though these are estimates and not guarantees.
Tap a question to reveal the answer.
The 2030 forecast shows a min of $0.3362, an average of $0.5356, and a max of $0.9177, with an estimated ROI of 23.2% and a bullish sentiment.
The outlook shows bullish sentiment in 2027 and beyond, with Avg prices rising through 2040 and 2050 and positive ROIs in multiple years (e.g., 2027 40%, 2028 63.5%, 2040 173.1%, 2050 242.2%). However, 2026 is Neutral, and these figures are estimates, not guarantees.
Yes. The forecast shows several years with max prices above $1, including 2033 at $1.60 and 2034 at $1.67, and further highs of $2.55 (2040) and $3.42 (2050).
Current price is $0.4346 and the market cap is $64.05M.
The 2050 forecast shows an average price of $1.49, a minimum of $0.6692, a maximum of $3.42, and an ROI of 242.2% with bullish sentiment.
Immutep Limited Community Discussion
0Share your Immutep Limited price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.